Sublingual Atropine Sulfate Use for Sialorrhea in Pediatric PatientsFunding None.
09 December 2019
16 February 2020
07 April 2020 (online)
Sialorrhea is a frequent problem and may lead to aspiration in patients with swallowing dysfunction. We aimed to assess the effectiveness and safety of sublingual atropine sulfate treatment in pediatric patients with sialorrhea. The medical records of patients who had received sublingual atropine sulfate between January 2015 and January 2016 were reviewed retrospectively. The demographic properties, diagnosis, invasive or noninvasive mechanical ventilation need, and the presence of tracheotomy were assessed. Response rates to sublingual atropine were measured using the Teacher Drooling Scale (TDS). Pre and post-treatment drooling scores were compared. Atropine sulfate ampoule was administered at 20 µg/kg/dose. Minimum dose was 0.25 mg, while maximum dose was 0.03 mg/kg.Thirty-five pediatric patients with sialorrhea who had received sublingual atropine sulfate were identified; however, TDS scores had been recorded in only 20 of them. The median age of the patients was 25 months (3–78 months; 7 girls, 13 boys). Sixteen (80%) patients were on invasive mechanical ventilation and seven (30%) had tracheotomy. Nineteen patients had a neurodevelopmental disorder and only one patient had oral and esophageal lesions due to corrosive material intake. The median TDS score prior to sublingual atropine sulfate treatment was 5, and it decreased to 3 on the second day of treatment, a change that was statistically significant (p < 0.001). No side effects were observed. Sublingual atropine sulfate is safe and effective in the short-term treatment of sialorrhea; however, randomized placebo controlled and long-term follow-up studies are necessary.
The hospital's Ethics Review Board, considering a retrospective study, waived the need for patient consent for the study.
- 1 Rapoport A. Sublingual atropine drops for the treatment of pediatric sialorrhea. J Pain Symptom Manage 2010; 40 (05) 783-788
- 2 Formeister EJ, Dahl JP, Rose AS. Surgical management of chronic sialorrhea in pediatric patients: 10-year experience from one tertiary care institution. Int J Pediatr Otorhinolaryngol 2014; 78 (08) 1387-1392
- 3 Norderyd J, Graf J, Marcusson A. , et al. Sublingual administration of atropine eyedrops in children with excessive drooling - a pilot study. Int J Paediatr Dent 2017; 27 (01) 22-29
- 4 Hockstein NG, Samadi DS, Gendron K, Handler SD. Sialorrhea: a management challenge. Am Fam Physician 2004; 69 (11) 2628-2634
- 5 Walshe M, Smith M, Pennington L. Interventions for drooling in children with cerebral palsy. Cochrane Database Syst Rev 2012; 11: CD008624
- 6 Comley C, Galletly C, Ash D. Use of atropine eye drops for clozapine induced hypersalivation. Aust N Z J Psychiatry 2000; 34 (06) 1033-1034
- 7 Antonello C, Tessier P. Clozapine and sialorrhea: a new intervention for this bothersome and potentially dangerous side effect. J Psychiatry Neurosci 1999; 24 (03) 250
- 8 Crysdale WS, Raveh E, McCann C, Roske L, Kotler A. Management of drooling in individuals with neurodisability: a surgical experience. Dev Med Child Neurol 2001; 43 (06) 379-383
- 9 De Simone GG, Eisenchlas JH, Junin M, Pereyra F, Brizuela R. Atropine drops for drooling: a randomized controlled trial. Palliat Med 2006; 20 (07) 665-671
- 10 Asai M, Katsube Y, Takita Y. , et al. Intravenous atropine treatment in hypertrophic pyloric stenosis: evaluation by clinical course and imaging. J Nippon Med Sch 2007; 74 (01) 50-54
- 11 Gervais HW, el Gindi M, Radermacher PR. , et al. Plasma concentration following oral and intramuscular atropine in children and their clinical effects. Paediatr Anaesth 1997; 7 (01) 13-18
- 12 Saarnivaara L, Kautto UM, Iisalo E, Pihlajamäki K. Comparison of pharmacokinetic and pharmacodynamic parameters following oral or intramuscular atropine in children. Atropine overdose in two small children. Acta Anaesthesiol Scand 1985; 29 (05) 529-536
- 13 Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord 2002; 17 (06) 1318-1320
- 14 Al-Memar AY, Roy D, Powel A, Pall HS. Treatment with atropine sulphate 1% drops in the management of bulbar MND. J Neurol Neurosurg Psychiatry 1998; 64: 704